STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany
Current clinical pharmacology | 17 Feb 2021
LJ Lehner, K Kalb, K Weigand, U Pein, P Schenker, W Seeger, R Roehle, K Dienes, F Halleck and K Budde
Tacrolimus HEXAL®/Crilomus® is an approved generic immunosuppressant for the prevention and treatment of rejection following renal transplantation. For safe and socioeconomically efficient conversion from the innovator to generic formulation, high-quality data are necessary, in view of the different and country-specific comorbidities and pharmacokinetics in kidney transplant recipients.
* Data courtesy of Altmetric.com